Estrogen receptor α mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death

Cancer Research

Volumn 67, Issue 11, 2007, Pages 5337-5344

  Sui, Meihua ^a   Huang, Yi ^b   Ben, Ho Park ^b   Davidson, Nancy E ^b   Fan, Weimin ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PACLITAXEL;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL DEATH; CELL LINE; CELL STRAIN MCF 7; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS INHIBITION; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HUMANS; MICROTUBULES; MITOSIS; PACLITAXEL; TRANSFECTION;

EID: 34347233468     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4582     Document Type: Article

References (43)

1. Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 1987;8:29-43.
2. Allegra JC, Lippman ME, Simon R, et al. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 1979;63:1271-7.
3. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-87.
4. Paik S, Hartmann DP, Dickson RB, Lippman ME. Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Res Treat 1994;31:301-7.
5. Kurebayashi J. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 2003;10:112-9.
6. Murphy L, Cherlet T, Lewis A, Banu Y, Watson P. New insights into estrogen receptor function in human breast cancer. Ann Med 2003;35:614-31.
7. Maehara Y, Emi Y, Sakaguchi Y, et al. Estrogen-receptor-negative breast cancer tissue is chemosensitive in vitro compared with estrogen-receptor-positive tissue. Eur Surg Res 1990;22:50-5.
8. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003;88:406-12.
9. Lippman ME, Allegra JC, Thompson EB, et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978;298:1223-8.
10. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67.
11. Stearns V, Singh B, Tsangaris T, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003;9:124-33.
12. Cocquyt VF, Schelfhout VR, Blondeel PN, et al. The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer. Med Oncol 2003;20:221-31.
13. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
14. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 1994;344:1267-72.
15. Luck HJ, Roche H. Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Crit Rev Oncol Hematol 2002;44 Suppl:S15-30.
16. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
17. Razandi M, Pedram A, Levin ER. Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol 2000;14:1434-47.
18. Huang Y, Fang Y, Dziadyk JM, Norris JS, Fan W. The possible correlation between activation of NF-κB/ IκB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis. Oncol Res 2002;13:113-22.
19. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-nB/InB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000;60:4426-32.
20. Huang Y, Fan W. InB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 2002;61:105-13.
21. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-86.
22. Robertson JF. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer. J Steroid Biochem Mol Biol 2001;79:209-12.
23. Abukhdeir AM, Blair BG, Brenner K, et al. Physiologic estrogen receptor a signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res Treat 2006;99:23-33.
24. Huang Y, Keen JC, Pledgie A, et al. Polyamine analogues down-regulate estrogen receptor α expression in human breast cancer cells. J Biol Chem 2006;281:19055-63.
25. Cheng L, Zheng S, Raghunathan K, et al. Characterisations of Taxol-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 1995;2:249-57.
26. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
27. Sui M, Fan W. Combination of γ-radiation antagonizes the cytotoxic effects of vincristine and vinblastine on both mitotic arrest and apoptosis. Int J Radiat Oncol Biol Phys 2005;61:1151-8.
28. Sui M, Chen F, Chen Z, Fan W. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 2006;119:712-7.
29. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
30. Sui M, Dziadyk JM, Zhu X, Fan W. Cell cycle-dependent antagonistic interactions between paclitaxel and γ-radiation in combination therapy. Clin Cancer Res 2004;10:4848-57.
31. Fan W, Cheng L, Norris JS, Willingham MC. Glucocorticoids selectively inhibit taxol-induced apoptosis in a human breast cancer cell line. Cell Pharmacol 1996;3:435-40.
32. Sui M, Xiong X, Kraft AS, Fan W. Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther 2006;5:1015-21.
33. Davidson NE, Gelmann EP, Lippman ME, Dickson RB. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1987;1:216-23.
34. Fan W, Schandl CA, Cheng L, Norris JS, Willingham MC. Glucocorticoids modulate Taxol cytotoxicity in human solid tumor cells. Cell Pharmacol 1996;3:343-8.
35. Fan W, Sui M, Huang Y. Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: mechanisms and its clinical impact. Curr Med Chem 2004;11:403-11.
36. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A 1995;92:4507-11.
37. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
38. Pines J, Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 1989;58:833-46.
39. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005;14 Suppl 1:35-48.
40. Dai Z, Huang Y, Sadee W. Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem 2004;4:1347-56.
41. Dougherty MK, Schumaker LM, Jordan VC, et al. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 2004;3:460-7.
42. Zajchowski DA, Sager R, Webster L. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res 1993;53:5004-11.
43. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U. Mutual regulation of the transcriptional activator NF-κ B and its inhibitor, InB-a. Proc Natl Acad Sci U S A 1993;90:2532-6.